STOCK TITAN
  1. Home
  2. News
  3. CNTB

Connect Biopharma Holdings Ltd - CNTB STOCK NEWS

Welcome to our dedicated news page for Connect Biopharma Holdings (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Connect Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Connect Biopharma Holdings's position in the market.

News
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Connect Biopharma reported positive clinical data for rademikibart in asthma and atopic dermatitis, with plans for FDA meetings in Q2 2024. The company granted exclusive rights to Simcere for development in Greater China, with strong financials supporting operations until at least 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.4%
Tags
earnings
-
News
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
Rhea-AI Summary
Connect Biopharma Holdings (CNTB) announces participation in H.C. Wainwright conference to discuss therapies for chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
-
News
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
Rhea-AI Summary
Connect Biopharma appoints James Huang, a seasoned biotech expert, to its Board of Directors. Huang brings over 30 years of experience in the industry and will play a key role in advancing the company's pipeline of therapies for chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
management
News
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma. The trial met its primary endpoint, showing significant improvement in lung function at Week 12 with both doses of rademikibart. The study demonstrated strong and significant improvement in asthma control, with both doses showing early and sustained improvement through Week 24. The safety results suggest rademikibart was generally well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
News
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on December 12, 2023, before market open. The Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data, featuring Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
News
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
Rhea-AI Summary
Connect Biopharma (CNTB) and Simcere Pharmaceutical (PR: Simcere Pharmaceutical Group Ltd.) have entered into an exclusive license and collaboration agreement for the development and commercialization of rademikibart in Greater China. Rademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases. Connect Biopharma will receive a ¥150 million RMB (US$ 21 million) upfront payment, up to ¥875 million RMB (US$ 120 million) upon achieving certain development and commercial milestones, in addition to royalties up to low double-digit percentages of net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
News
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Rhea-AI Summary
Connect Biopharma Holdings Limited (CNTB) announced positive topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD). Rademikibart continued to be well tolerated over 52 weeks of treatment, with approximately 90% of patients on Q4W dose maintaining both IGA 0/1 and EASI-75 through Week 52.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
News
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announces topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis. The company will host a conference call and webcast presentation to discuss the trial results on Tuesday, November 21, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
News
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Connect Biopharma reports financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
earnings
News
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Rhea-AI Summary
Connect Biopharma Holdings received a letter from Nasdaq indicating that its bid price for ADSs had closed below the minimum $1.00 per share requirement for continued listing. The company has until March 11, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
Stock CNTB logo
Connect Biopharma Holdings Ltd

Nasdaq:CNTB

CNTB Rankings

#4490 Ranked by Market Cap
#406 Ranked by Stock Gains
N/A Ranked by Dividends

CNTB Stock Data

94.72M
16.02M
41.29%
44.03%
0.21%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego

About CNTB

suzhou connect biopharmaceuticals, ltd. is a pharmaceuticals company based out of 10th floor, xiangtang development building, #3 chaoyang dong rd, taicang, china.